GetPortalImpactFactorByIdResp(projectId=1, id=a7093285, cover=https://img.medsci.cn/images/journal/cover/2021/LqY_202109271315261270.jpg, fullname=INVESTIGATIONAL NEW DRUGS, abbr=INVEST NEW DRUG, pyear=1983, frequence=Bimonthly, articleNumbers=1718, citedSelf2015=1.6, acceptanceRate=null, submissionToAcceptance=null, averageReviewTime=平均3月, reviewFee=null, pageFee=null, publishedRatio=2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%), issn=0167-6997, greenSci=https://www.greensci.net/search?kw=0167-6997, scijournal=https://www.scijournal.org/impact-factor-of-INVEST-NEW-DRUG.shtml, medsciHotlightString=null, medsciHotlightRealtime=7.243, medsciHotlight=6.476, medsciHotlight5year=5.81002, citescore=5.6, hIndex=87, impactFactor=3.4, orgnization=Kluwer Academic Publishers, orgnizationUrl=http://springerlink.com, country=Netherlands, countryCn=荷兰, isOa=0, isOaString=否, sciScie=Science Citation Index|Science Citation Index Expanded|Current Contents - Clinical Medicine|Current Contents - Life Sciences|BIOSIS Previews, bigclassCas=医学 3区, smallclassCas=医学 3 区, website=https://www.springer.com/medicine/internal/journal/10637, websiteHits=10112, guideForAuthor=null, guideForAuthorHits=24, submitWebsite=, submitWebsiteHits=11, content=The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist toxicologist pharmacist pharmacologist biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents. Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents the journal is not adverse to publishing clinical trials with negative results. Investigational New Drugs cuts across all the usual lines or subdisciplines providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development., totalCites=5844, brief=INVEST NEW DRUG杂志医学行业，“<strong><a target="_blank" href="/sci/index.do?smallclass=药学" >药学</a></strong>”子行业的中等级别杂志, articleType=论著为主，其它类型文章约占5-10%, medsciHeat=<span style="color: #990000;">暗红</span>, medsciComment=INVEST NEW DRUG杂志级别还可以，但是相对来说，比较冷门，关注人数偏少，有些可能是国内不太熟悉，但该杂志在国际仍然有相当知晓度的。因为缺少中国人投稿，稿源可能未必丰富，发表有可能有很大的机会哦。, medsciExplanation=MedSci期刊指数是根据中国科研工作者（含医学临床，基础，生物，化学等学科）对SCI杂志的认知度，熟悉程度，以及投稿的量等众多指标综合评定而成。当然，具体的，您还可以结合“<a href='https://www.medsci.cn/sci/submit.do?id=a7093285'>投稿经验系统</a>”，进行综合判断，这更是大家的实战经验，值得分享和参考。<br> 注意，上述MedSci期刊指数采用MedSci专利技术，由计算机系统自动计算，并给出建议，存在不准确的可能，仅供您投稿选择杂志时参考。, tags=[ImpactFactorTagDto(id=119, tagName=肿瘤, createdHits=4), ImpactFactorTagDto(id=137, tagName=药物, createdHits=2), ImpactFactorTagDto(id=1517, tagName=临床研究, createdHits=1)], citeScoreList=[GetImpactFactorCiteScoreListResponse(year=2016, citescore=3.24), GetImpactFactorCiteScoreListResponse(year=2017, citescore=3.71), GetImpactFactorCiteScoreListResponse(year=2018, citescore=2.87), GetImpactFactorCiteScoreListResponse(year=2019, citescore=5.0), GetImpactFactorCiteScoreListResponse(year=2020, citescore=5.6)], medsciIndexList=[GetImpactFactorMedsciIndexListResponse(year=2020, medsciHotlight=5.195), GetImpactFactorMedsciIndexListResponse(year=2021, medsciHotlight=7.309), GetImpactFactorMedsciIndexListResponse(year=2022, medsciHotlight=7.276), GetImpactFactorMedsciIndexListResponse(year=2023, medsciHotlight=6.449), GetImpactFactorMedsciIndexListResponse(year=2024, medsciHotlight=7.243)], citeScoreGradeList=[GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Pharmacology (medical) , rank=61/232), GetImpactFactorCiteScoreGradeResponse(smallClass=Pharmacology, Toxicology and Pharmaceutics - Pharmacology , rank=96/300), GetImpactFactorCiteScoreGradeResponse(smallClass=Medicine - Oncology , rank=114/321)], totalJcrAreaList=[GetImpactFactorCiteScoreGradeResponse(smallClass=ONCOLOGY, rank=Q2), GetImpactFactorCiteScoreGradeResponse(smallClass=PHARMACOLOGY & PHARMACY, rank=Q2)], pmcUrl=https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0167-6997[ISSN], pubmedUrl=https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=INVESTIGATIONAL NEW DRUGS[ta], article_number=156, article_number_cn=64, earlyWarning=null, linkOutUrl=null, isJournalMember=false, unscrambleContent=null, dayViewCount=false, endexampletyle=暂无数据)